Emergent BioSolutions (EBS) Net Income towards Common Stockholders (2011 - 2026)

Emergent BioSolutions' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 90.0% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at -$8.6 million (up 93.47% YoY), while the FY2025 annual figure was $52.6 million, up 127.6% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $6.8 million, up from -$54.6 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $114.8 million in Q3 2024, with the low at -$283.1 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$49.5 million (2023), against an average of -$65.1 million.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 4932.43% in 2023, then soared 655.56% in 2025.
• Emergent BioSolutions' Net Income towards Common Stockholders stood at -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then slumped by 74.44% to -$54.6 million in 2025, then surged by 112.45% to $6.8 million in 2026.
• Business Quant data shows EBS's Net Income towards Common Stockholders at $6.8 million in Q1 2026, -$54.6 million in Q4 2025, and $51.2 million in Q3 2025.